SCHEDULE: Adage Capital Discloses 8.5% Stake in Fulcrum Therapeutics

Adage Capital Management, L.P. and its principals have disclosed a beneficial ownership of 8.5% in Fulcrum Therapeutics, Inc. common stock.

Summary

• Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 4,589,000 shares of Fulcrum Therapeutics, Inc. Common Stock.
• This ownership represents 8.50% of the company's outstanding Common Stock.
• The percentage is calculated based on 53,979,306 shares of Common Stock outstanding as of April 24, 2025, as reported in Fulcrum Therapeutics' Quarterly Report on Form 10-Q.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the company's performance or prospects.

Positives

• The disclosure of a significant institutional investor, Adage Capital Management, holding an 8.5% stake may signal confidence in Fulcrum Therapeutics, Inc.

Risks

• The Reporting Persons explicitly state that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer, indicating a passive investment approach.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Fulcrum Therapeutics, Inc. or the Reporting Persons regarding the company's future performance.

Industry Context

This filing is a routine disclosure of institutional ownership in a publicly traded biotechnology company, Fulcrum Therapeutics, Inc. Such disclosures are common in the industry as investment funds take positions in companies.

Comparison to Industry Standards

• Institutional ownership by investment managers like Adage Capital Management is a standard practice across the biotechnology and pharmaceutical sectors.
• A beneficial ownership stake of 8.5% is a significant position for an institutional investor, indicating a notable allocation to Fulcrum Therapeutics within their portfolio, comparable to other substantial institutional holdings seen in similar-sized biotech firms.

Stakeholder Impact

• Shareholders are informed of a significant institutional investor's stake, which can influence market perception and potentially liquidity.

Key Dates

Keywords

Fulcrum Therapeutics, Adage Capital Management, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investment, biotechnology, pharmaceuticals